GMED

Medtronic plc MDT reported first-quarter fiscal 2027 adjusted earnings per share (EPS) of $1.45 per share, which rose 15.1% year over year and topped the Zacks Consensus Estimate by 4.32%. The metric excludes certain one-time adjustments, including amortization of intangible assets, restructuring and associated costs, as well as acquisition and divestiture-related items. On a GAAP basis, EPS came in at $1.14, up from 81 cents a year earlier. Revenues rose 13.7% year over year to $9.76 billion and beat the consensus mark by 3.02%. The quarter included an extra fiscal week, which benefited organic growth by approximately $570 million. Following the announcement today, MDT shares rose nearly 5% in pre-market trading. Cardiovascular revenues totaled $3.93 billion in the first quarter of fiscal 2027, up 19.5% year over year on a reported basis and 18.9% organically. Within this, Electrophysiology Therapies revenues rose 29.1%, while Interventional Cardiology Therapies revenue were up 6.5% organically. CardioVascular Surgery and Peripheral Vascular Health revenues advanced 8.1% and 11% respectively, on an organic basis. Neuroscience revenues came in at $2.68 billion, up 10.3% reported and 9.3% organically. Cranial & Spinal Technologies led the portfolio with 12.9% organic growth. Specialty Therapies revenues increased 7.4% organically, while Neuromodulation posted 3.3% organic growth. Medtronic PLC price-consensus-eps-surprise-chart | Medtronic PLC Quote Medical Surgical revenues were $2.28 billion, up 10% year over year and 10.2% organically. Surgical & Endoscopy revenues increased 9% organically, while Acute Care & Monitoring revenues rose 14.2% organically. Diabetes revenues jumped 16.9% to $843 million, with organic growth of 14.9%. U.S. revenues rose 16.1% to $4.91 billion, with organic growth of 15.8%. U.S. Cardiovascular was particularly strong, increasing 25.3%, as Electrophysiology Therapies revenues climbed 41.2%. International revenues advanced 11.4% to $4.85 billion and grew 11.6% organically. International Diabetes recorded 16.8% organic growth, while Cardiovascular increased 13.7%, highlighting strength across major overseas businesses. The gross margin in the reported quarter remained flat year over year at 65% despite a 13.8% increase in the cost of products sold, excluding amortization of intangible assets, to $3.42 billion. Research and development expenses rose 6.2% year over year to $771 million. Selling, general and administrative expenses increased 14% to $3.20 billion. The adjusted operating margin expanded 10 basis points year over year to 23.7%. Medtronic raised its fiscal 2027 organic revenue growth outlook to 7.25%-7.75% from the prior 6.75%-7.25% range. The company also lifted adjusted EPS guidance to $5.94-$6.00 from the prior $5.90-$6.00 outlook. The guidance incorporates an estimated neutral to 1% accretive foreign currency impact based on recent exchange rates. Medtronic also highlighted recent acquisitions of Scientia Vascular and SPR Therapeutics and continued investment in growth platforms. The Zacks Consensus Estimate projects fiscal 2027 revenues of $38.64 billion, up 6.3% from the fiscal 2026 levels, while EPS is expected to rise 7.4% to $5.94. Medtronic delivered better-than-expected earnings and revenues in the first quarter of 2027. Cardiovascular remained the key growth engine, with strong performances in Cardiac Rhythm Management and Cardiac Ablation Solutions. Neuroscience, Medical Surgical and Diabetes also delivered healthy organic growth. Management cited strong operating performance, continued innovation investments, portfolio development and commercial execution in supporting the improved 2026 outlook. During the quarter, Medtronic completed the acquisitions of Scientia Vascular and SPR Therapeutics. The company announced an expanded CE Mark indication for the Affera Mapping and Ablation System and Sphere-9 Catheter for treating ventricular arrhythmias. MDT also received FDA clearance for its next-generation Touch Surgery Aide computing platform. Medtronic stated that it has entered into a strategic partnership with Cornerstone Robotics to broaden access to robotic-assisted surgery and also announced a strategic investment in Pi-Cardia, strengthening its portfolio development efforts. Medtronic currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Globus Medical GMED, Envista NVST and Teleflex TFX. Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here. GMED has an earnings yield of 6% compared to the industry’s negative 1.3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 27.9%. Envista, carrying a Zacks Rank #2 (Buy) at present, posted second-quarter 2026 adjusted earnings of 41 cents per share, exceeding the Zacks Consensus Estimate by 24.2%. Revenues of $730.5 million topped the Zacks Consensus Estimate by 2.2%. NVST has an estimated long-term earnings growth rate of 13.8% compared with the industry’s 10.8% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 19.4%. Teleflex, carrying a Zacks Rank #2 at present, posted a second-quarter 2026 adjusted EPS of $1.76, exceeding the Zacks Consensus Estimate by 37.5%. Revenues of $570.3 million outperformed the Zacks Consensus Estimate by 1.9%. TFX has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.9% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Teleflex Incorporated (TFX) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Envista Holdings Corporation (NVST) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Veeva Systems, Inc. VEEV reported adjusted earnings per share (EPS) of $2.35 for the second quarter of fiscal 2027, which increased 18.1% from the year-ago figure of $1.99. Adjusted EPS beat the Zacks Consensus Estimate by 5.9%. GAAP EPS in the fiscal second quarter was $1.66, up 39.5% from the year-ago period’s $1.37. VEEV’s second-quarter revenues rose 17.6% to $928 million and topped the consensus estimate by 2.7%. Growth reflected strength across subscriptions and services, while Vault CRM ended the quarter with more than 180 customers live. Shares of the company surged more than 9% in yesterday’s after-market trading. The stock gained 9.7% in the year-to-date period compared with the industry’s growth of 7.7%. The S&P 500 Index has increased 11.6% in the same time frame. Image Source: Zacks Investment Research The fiscal second-quarter revenue growth was driven by strength across Subscription services and Professional services and other revenues. Subscription services revenues increased 16.3% year over year to $766.8 million. Professional services and other revenues advanced 24.1% year over year to $161.2 million. In the quarter under review, Veeva Systems’ gross profit increased 17.2% year over year to $695.9 million. However, the gross margin contracted 30 basis points (bps) to 75%. Sales and marketing expenses increased 15.8% year over year to $126.7 million. Research and development expenses rose 15.7% year over year to $222.9 million, while general and administrative expenses declined 25.6% year over year to $71.3 million. Total operating expenses of $420.9 million increased 5.8% year over year. Operating profit totaled $275 million, up 40.4% from the prior-year quarter. The operating margin in the fiscal second quarter expanded 480 bps to 29.6%. VEEV’s Financial Position The company exited second-quarter fiscal 2027 with cash and cash equivalents and short-term investments of $7.24 billion compared with $7.31 billion at the fiscal first quarter of 2027-end. Cumulative net cash provided by operating activities at the end of the quarter was $1.37 billion compared with $1.12 billion a year ago. Veeva Systems has issued its financial outlook for the fiscal third quarter and raised its guidance for fiscal 2027. For the fiscal third quarter, the company expects total revenues in the range of $932-$935 million. Subscription revenues are projected to be approximately $782 million, while Professional services and other revenues are anticipated between $150 million and $153 million. Adjusted EPS is projected between $2.33 and $2.34. For fiscal 2027, Veeva Systems now expects revenues between $3.682 billion and $3.687 billion. Subscription revenues are projected to be approximately $3.08 billion, comprising Commercial Solutions subscription revenues of around $1.405 billion and R&D and Quality Solutions subscription revenues of approximately $1.675 billion. Professional services and other revenues are expected in the range of $602-$607 million. Adjusted EPS is now expected to be approximately $9.21. Veeva Systems Inc. price-consensus-eps-surprise-chart | Veeva Systems Inc. Quote Veeva Systems exited the second quarter of fiscal 2027 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The company also raised its fiscal 2027 outlook. Strong execution across Commercial Solutions and R&D and Quality Solutions, along with continued momentum in newer growth areas, remained encouraging. Veeva Systems continued to make notable progress with Vault CRM. The platform recorded its best quarter ever, with more than 180 customers live, including five top 20 biopharmas. In August, two additional top 20 biopharmas and one large enterprise biopharma committed to Vault CRM, taking total top 20 commitments to 12 globally. A top 20 biopharma also deployed Vault CRM and Agentic Call Report across its entire U.S. field team during the quarter. The company also advanced its AI strategy. Veeva Falcon, its agentic labor platform for clinical, regulatory and safety functions, now has five early adopters and remains on track for initial go-lives this year. Veeva Systems also acquired Copli and launched Veeva Falcon MLR to automate content reviews. Vault AI added new standard agents, enhanced existing agents and introduced advanced tools for custom agent development in August. Management noted that customer interest in Falcon remains high, although product readiness and work with early adopters remain key near-term priorities. Momentum across Development Cloud and Quality Cloud also remained strong. A large enterprise biopharma selected Veeva EDC, extending its existing eTMF, CTMS and Study Startup foundation. Veeva Safety surpassed 100 customers and secured its second top 20 biopharma win for Safety Workbench. The Quality business added more than 30 customers, supported by at least 20 wins each across QualityDocs, QMS and Training. These developments underscore Veeva Systems’ continued expansion across clinical, safety and quality applications. VEEV carries a Zacks Rank #4 (Sell) at present. Some better-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and The Cooper Companies COO. Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here. GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%. West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%. WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%. The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%. COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

NeuroPace, Inc. NPCE reported a second-quarter 2026 loss per share of 18 cents, compared with a loss of 30 cents in the year-ago period. The figure beat the Zacks Consensus Estimate by 5.3%. Shares of NPCE were down approximately 2.3% during after-market trading following the second-quarter results. The company’s shares have lost 2.6% in the year-to-date period compared with the industry’s decline of 5.9%. However, the broader S&P 500 Index has increased 12.5% in the same time frame. Image Source: Zacks Investment Research NeuroPace registered revenues of $22.8 million in the second quarter, up 17.1% year over year. Growth was led by the RNS System, while active prescribers, accounts and the patient pipeline reached record highs. The figure surpassed the Zacks Consensus Estimate by 0.6%. RNS System revenues totaled $22.5 million, up 21.3% year over year. The increase primarily reflected more units sold, driven by a higher number of initial implants and replacement procedures. Service revenues were $302,000, down from $937,000 a year ago. Following the DIXI Medical wind-down, NeuroPace now presents that business as discontinued operations. In the quarter under review, NeuroPace’s adjusted gross profit increased 16.1% year over year to $19 million. Adjusted gross margin contracted 60 basis points (bps) to 83.4%, primarily due to slightly higher material costs, partly offset by favorable pricing. Sales and marketing expenses increased 5.5% year over year to $12.1 million, while research and development expenses rose 0.8% to $6.9 million. General and administrative expenses decreased 17.2% year over year to $5.0 million. Adjusted operating expenses of $21.9 million increased 2.5% year over year. The adjusted operating loss narrowed to $2.8 million from $5 million in the prior-year quarter. NeuroPace ended second-quarter 2026 with total cash, cash equivalents and short-term investments of $51.7 million, compared with $53.9 million at the end of first-quarter 2026. Cumulative net cash used in operating activities at the end of second-quarter 2026 was $9.8 million compared with $9.6 million a year ago. Management raised full-year 2026 revenue guidance to $99.5-$101.5 million from $99-$101 million. The increase reflects expected service revenues of about $1 million, up from roughly $500,000 previously, while the RNS revenue growth outlook remains 21%-23%. The Zacks Consensus Estimate is pegged at $99.9 million. The adjusted gross margin is now expected to be 82%-83%, up from the previous guidance of 81.5%-82.5%. Adjusted operating expenses are projected at $90 million-$92 million, unchanged from the prior outlook and excluding approximately $10 million in stock-based compensation. The adjusted EBITDA loss is now expected in the range of $7.5 million-$8.5 million, an improvement from the previous guidance of a loss between $8.5 million and $9.5 million. NeuroPace, Inc. price-consensus-eps-surprise-chart | NeuroPace, Inc. Quote NPCE exited the second quarter of 2026 with continued momentum in its core RNS business, supported by increased adoption within the existing focal epilepsy indication. The company reached record highs in active prescribers, accounts and patient pipeline, underscoring progress in its commercial expansion efforts. Innovation remained a key focus during the quarter. NeuroPace launched ECoG Assistant, the first in its planned suite of AI-based clinical decision-support tools. The platform leverages the company’s proprietary dataset of more than 27 million intracranial EEG recordings and 35,000 patient implant years to simplify data review and support individualized therapy decisions. NeuroPace continued to advance its idiopathic generalized epilepsy opportunity. It published 18-month NAUTILUS data showing a 77% median reduction in generalized tonic-clonic seizures and is preparing for a Submission Issue Request meeting with the FDA regarding its PMA supplement. The company also cited 24-month data showing a 100% median reduction in GTC seizures among evaluable patients. Looking ahead, NeuroPace’s growth strategy centers on driving more than 20% growth in the core RNS business through prescriber expansion, higher utilization and commercial execution. Management also intends to deepen community penetration, advance AI-enabled personalized neuromodulation, prepare for potential indication expansion and maintain disciplined spending as it works toward cash flow breakeven. NPCE currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and The Cooper Companies COO. Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here. GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%. West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%. WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%. The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10.00%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%. COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NeuroPace, Inc. (NPCE) : Free Stock Analysis Report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Cardinal Health, Inc. CAH reported fourth-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.91, beating the Zacks Consensus Estimate by 20.3%. The bottom line improved 40% year over year, aided by higher operating earnings, IEEPA tariff refunds, a lower tax rate and a reduced share count. GAAP EPS in the quarter was $1.70 compared with $1.00 in the year-ago period. Full-year fiscal 2026 adjusted EPS was $11.26, up 37% compared to the figure at the end of the fiscal 2025 period. The company reported GAAP EPS of $7.23 in fiscal 2026, compared with $6.45 in the year-ago period. For the fiscal fourth quarter, revenues were up 6% on a year-over-year basis to $63.67 billion. The top line, however, missed the Zacks Consensus Estimate by 2.9%. For full-year fiscal 2026, CAH registered revenues of $254.25 billion, up 14% compared with fiscal 2025. Shares of CAH were up 3.7% in pre-market trading. The company’s shares have climbed 15.4% in the year-to-date period compared with the industry’s 5.9% rise and the S&P 500 Index’s 13.1% gain. Image Source: Zacks Investment Research Pharmaceutical and Specialty Solutions Pharmaceutical and Specialty Solutions revenues increased 6% year over year to $58.85 billion. The improvement was driven by brand and specialty pharmaceutical sales growth from existing customers. The segment’s profit totaled $645 million, up 21% from the year-ago period’s level. The upside was primarily driven by contributions from brand and specialty products and positive generics program performance. Global Medical Products and Distribution Revenues in this segment totaled $3.13 billion, down 2% year over year. The decline primarily reflected lower distribution volumes and the recognition of expected IEEPA tariff refund repayments to customers, partially offset by Cardinal Health brand growth. The segment reported a profit of $150 million compared with $70 million in the year-ago quarter. This improvement was primarily driven by IEEPA tariff refunds. Other This segment includes three operating segments — Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics. Revenues totaled $1.72 billion, up 7% year over year, driven by growth across all three operating segments. The segment’s profit amounted to $183 million, up 14% from the year-ago level. This upside was driven by growth in OptiFreight Logistics and at-Home Solutions. Gross profit increased 16% year over year to $2.56 billion. As a percentage of revenues, the gross margin in the reported quarter was approximately 4.0%, up almost 36 basis points year over year. Distribution, selling, general and administrative expenses totaled $1.63 billion, up 10% year over year. Operating income amounted to $729 million, up 70% year over year. Adjusted operating income increased 30% year over year to $935 million. The company exited the reported quarter with cash and cash equivalents of $4.86 billion compared with $3.94 billion at the end of the third quarter of fiscal 2026. Net cash provided by operating activities totaled $5.17 billion compared with $2.39 billion in the year-ago period. Cardinal Health raised its fiscal 2027 earnings guidance. CAH expects fiscal 2027 adjusted EPS in the range of $12.40-$12.60, implying growth of 13-15% from adjusted fiscal 2026 results excluding the IEEPA tariff refund benefit. The Zacks Consensus Estimate for the same is pegged at $12.04. The company expects revenues from the Pharmaceutical and Specialty Solutions segment to grow 3-5% year over year. Segmental profit is projected to increase 8-11%. Revenues from the Global Medical Products and Distribution segment are anticipated to grow 2-4%. Segmental profit is expected to be between $200 million and $220 million. Revenues from the Other segment are likely to increase 11-13%. Segmental profit is projected to grow 15-18%. Cardinal Health, Inc. price-consensus-eps-surprise-chart | Cardinal Health, Inc. Quote Cardinal Health delivered mixed fourth-quarter fiscal 2026 results, with earnings surpassing estimates while revenues missed the same. Performance benefited from strength in Pharmaceutical and Specialty Solutions, while the company’s higher-margin growth businesses continued to expand across at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight Logistics. Cardinal Health is strengthening these growth platforms through tuck-in acquisitions of Strive Medical and AdaptHealth’s Diabetes Health business. The company launched an outbound pharmacy shipping solution at OptiFreight Logistics and continues to invest in expanding PET and theranostics capabilities within Nuclear and Precision Health Solutions. On the commercial front, CAH renewed its long-term wholesaler distribution contract with Kroger and plans to open a new Indianapolis distribution center in fiscal 2027 featuring advanced robotics and automation to increase capacity and operational flexibility. Cardinal Health also remains focused on shareholder returns, completing $1.4 billion of share repurchases in fiscal 2026 and announcing an additional $5 billion repurchase authorization. Supported by continued investments in growth and a positive earnings outlook, the company is targeting sustained expansion across its core and higher-margin businesses. Cardinal Health carries a Zacks Rank #2 (Buy) at present. Some other top-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and The Cooper Companies COO. Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here. GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%. West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%. WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%. The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10.00%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%. COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report The Cooper Companies, Inc. (COO) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in Globus Medical, Inc.? Here are five stocks we like better. Q2 revenue rose 6% to $789.6 million, while record non-GAAP EPS increased 56% to $1.34 and adjusted EBITDA margin expanded to 35.4%. Spine and trauma growth offset declines in enabling technologies and Nevro. Musculoskeletal revenue grew 8%, led by 7% U.S. spine growth, 12% constant-currency international spine growth and a 31% increase in trauma revenue. Robotic-equipment placements also increased despite lower reported enabling-technologies revenue as the company shifts toward leasing and rental models. Globus reaffirmed 2026 revenue guidance of $3.18 billion to $3.22 billion but raised its adjusted EPS outlook to $4.95-$5.05. The company also repurchased $136.1 million of stock during the quarter, while continuing efforts to improve Nevro’s sales execution and margins. 3 Medical Device Stocks Giving Investors a Different Healthcare Play Globus Medical (NYSE:GMED) reported second-quarter 2026 revenue of $789.6 million, up 6% from a year earlier, as growth in its spine and trauma businesses helped offset declines in enabling technologies and Nevro sales. The company reaffirmed its full-year revenue outlook while raising its adjusted earnings forecast, citing margin expansion and operating leverage in the first half. Fully diluted GAAP earnings per share were $1.10, while non-GAAP diluted earnings per share reached a quarterly record of $1.34, up 56% from the prior-year quarter. Adjusted EBITDA margin increased to 35.4% from 28.0% a year earlier. → Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling “We completed an exceptional Q2, positioning us for a strong 2026 as we move into the second half of the year,” President and Chief Executive Officer Keith Pfeil said on the company’s earnings call. Musculoskeletal revenue totaled $763.5 million, rising 8% year over year and 4% sequentially. Excluding Nevro, the company’s base business grew 9%, led by 7% growth in U.S. spine revenue and 14% reported growth in international spine revenue. → 4 Oil and Gas ETF Plays as Prices Stay Sky-High Pfeil said U.S. spine growth reflected procedural volumes, competitive sales-force recruiting, robotic pull-through and product launches. The company said competitive hires in the second quarter were double the first-quarter level and represented its second-highest onboarding total in eight quarters. Several U.S. spine products posted double-digit growth, including SABLE, ELSA, HEDRON C, Reline-C and Reline Open, according to management. Its DuraPro power tools product grew more than 250% during the quarter. → No Hangover: Revisiting Microsoft One Week After Earnings International spine revenue rose 12% on a constant-currency basis. The company cited mid-teens growth in Italy, Spain and Poland, along with broad-based growth in Asia-Pacific markets and gains in Brazil and Colombia. Pfeil said improved set deliveries and inventory availability supported deeper penetration in markets where Globus already operates. Trauma revenue increased 31% year over year and 18% sequentially. Management attributed the performance to share gains in its core trauma portfolio and normalized supply for the PRECICE product line, which enabled the company to meet U.S. demand and expand availability in markets outside the United States. The company launched three products in the quarter: the AUTOBAHN Hip Fastener and TENSOR Suture Button System for trauma procedures, as well as Reline 1 for minimally invasive spine procedures. Enabling Technologies revenue was $26.1 million, down 26% year over year. Chief Financial Officer Kyle Kline said the decline was tied to Globus’ strategy of offering customers more flexible ways to acquire capital equipment rather than relying principally on cash sales. While revenue from the segment declined, management said placements of ExcelsiusGPS and ExcelsiusHub units—whether sold, leased or rented—rose 11% sequentially and 25% from a year earlier. More than 137,000 procedures have now been performed using the company’s robotic technology. Pfeil said the company views 2026 as a transition year for the capital-acquisition strategy. The longer-term objective is to increase implant, disposable and service revenue after equipment is installed and customers are trained. “The goal here is to drive enduring musculoskeletal growth,” Pfeil said, specifically pointing to U.S. and international spine opportunities. Nevro revenue declined 14.3% year over year and $1.7 million sequentially, though Pfeil said second-quarter sales were essentially flat with the first quarter and in line with the company’s expectations. Globus acquired Nevro in 2025 and has been integrating its pain-management business into its operating model. Management said it filled roughly 75% of open Nevro sales roles during the second quarter. Its near-term focus is on recruiting, training and raising trial volumes, which Pfeil said are expected to improve through the second half and return to historical levels late in the fourth quarter. Kline said Nevro’s adjusted EBITDA margin improved to 22.4% in the second quarter from 11.8% in the first quarter and negative 1.4% in the prior-year quarter, reflecting cost-control and synergy actions implemented during 2025. Management said it expects trial-volume recovery by year-end and believes the business can improve its top-line performance by the end of 2026, but it did not provide a separate outlook for Nevro. GAAP gross margin was 66.8%, compared with 63.3% a year earlier. Adjusted gross margin rose 200 basis points to 69.4%, marking the company’s seventh consecutive quarter of expansion. Kline attributed the improvement to higher sales, favorable mix, manufacturing and supply-chain initiatives, and merger-related synergies, partly offset by higher freight costs. Globus reiterated its expectation for 2026 adjusted gross margin of 69% to 70%. Kline said the company expects to reach the low-70% range by the end of the year and targets a return to a mid-70% gross-margin profile in 2027. The company plans to increase research and development investment in the second half, with full-year R&D expense expected to be 5% to 6% of sales. Pfeil said the investments will span spine, trauma, joints, neuro, pain and software capabilities. Globus expects to launch its patient-specific SCRIPT lumbar spacers and rods later in the third quarter. Pfeil said the products can be produced in approximately seven to 10 days and will integrate with the company’s Excelsius technology platform and spinal implant systems. Globus reaffirmed 2026 revenue guidance of $3.18 billion to $3.22 billion, representing projected growth of 8.2% to 9.6% over 2025. Kline said the company remained cautious on the second half because of the enabling-technology business model transition, the ongoing Nevro recovery and more difficult comparisons in spine. The company raised its full-year non-GAAP diluted earnings-per-share forecast to $4.95 to $5.05 from $4.70 to $4.80. The revised range implies growth of 24.4% to 26.9% from 2025. Cash, cash equivalents and marketable securities totaled $840.5 million at June 30, up from $629.1 million at year-end 2025. During the quarter, Globus repurchased $136.1 million of stock, or 1.6 million shares, leaving $253.9 million under its existing repurchase authorization. Management said its capital-allocation priorities remain internal product development, investments in manufacturing and commercial infrastructure, share repurchases, and evaluation of complementary acquisitions. Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes. In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Globus Medical Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Globus Medical Inc (NYSE:GMED) delivered exceptional Q2 2026 results with revenue of $789.6 million, growing 6% as reported, and 9% growth in the base business excluding Nevro. The company achieved a record quarterly non-GAAP EPS of $1.34, growing 56% year-over-year, and adjusted EBITDA margin expanded 740 basis points to 35.4%. US Spine continued its strong performance with 7% growth, marking the fifth consecutive quarter of above-market growth, driven by competitive recruiting and product launches. International Spine grew 14% as reported, with double-digit growth across key EMEA markets, APAC, and LATAM, reflecting successful market penetration strategies. The company raised its full-year 2026 non-GAAP EPS guidance to $4.95-$5.05, up from $4.70-$4.80, reflecting strong margin expansion and operating leverage. Nevro sales declined 14.3% year-over-year and saw a sequential decline of $1.7 million, with the company expecting trial volume recovery only by late Q4 2026. Enabling Technologies revenue declined 26% in Q2, driven by a strategic shift towards more flexible capital acquisition models, which creates near-term revenue pressure. US Spine growth slowed to 7% from the prior 10% rate, with management noting more difficult year-over-year comparisons in the second half of 2026. The company chose not to raise its full-year revenue guidance despite the Q2 beat, citing caution around the enabling tech strategy shift and Nevro's stabilization. R&D expenses are expected to ramp significantly in the back half of 2026 to reach the 5%-6% of sales target, potentially impacting near-term profitability. Warning! GuruFocus has detected 4 Warning Signs with GMED. Is GMED fairly valued? Test your thesis with our free DCF calculator. Q: Can you provide an update on the U.S. Spine growth of 7% in Q2, which stepped down from the last couple of quarters, and if this is the more sustainable run rate going forward? A: Keith File, President and CEO: We came off a couple of strong quarters with basically 10% growth. As we get into the second half of the year, our comps get a little more difficult, but that doesn't take away from our confidence in the business. We see our U.S. Spine business performing really well and are confident as we look into the rest of the year, despite the tougher year-over-year comparisons. Q: You beat on the gross margin line and have talked about a return to a mid-70s adjusted gross profit profile. Over what time frame do you expect to achieve that? A: Kyle Klein, CFO: This is the seventh straight quarter of gross profit margin expansion. We expect to finish the year in the 69% to 70% range and see sequential uplift quarter after quarter. We're likely to touch the low 70s by the end of the year. Keith File added that they feel confident on getting back to the mid-70s in 2027, given the manufacturing and operations initiatives in place. Q: Can you talk about the Nevro cadence for the remainder of the year and the M&A strategy for that division? A: Keith File, President and CEO: The Nevro cadence is consistent with what we discussed last quarter. As we move through the rest of the year, we expect trial volumes to translate into sales starting to move higher in Q3 and Q4. On M&A, I have no specific comments on Nevro M&A. The focus right now is stabilizing the business and getting it back to a path of returning to growth. Q: Can you provide more color on the expectations for enabling tech growth in the back half, given the growing financing flexibility dynamic? A: Keith File, President and CEO: We don't break out guidance into parts and pieces, but our goal is to get our capital in the hands of customers to drive implant growth over the long-term. The capital will drive implant growth, disposables growth, and service growth, which will enhance sales in musculoskeletal. Q: Can you elaborate on the strength in OUS Spine and the level of confidence in accelerating growth in the back half? A: Keith File, President and CEO: We had some softer comps last year, but this year we are much happier with set deliveries and inventory availability, which has been a catalyst to go deeper in the countries we operate in. We think this is a strong business that can grow double-digits by going deeper where we are. The biggest improvement year-over-year has been set deliveries and inventory availability. Q: Can you comment on trends, demand, and volumes in the U.S. spine market year-to-date, and what does guidance assume for the market outlook? A: Keith File, President and CEO: The spine market appears healthy. We haven't seen any drop-off in procedural demand; it has remained pretty constant. Looking ahead, my view is that the market will continue to be fairly stable. There is still ample competition and it's a fragmented market, but it's operating in a healthy manner. We are confident in our U.S. Spine business. Q: On R&D spend for the year, you're keeping it at 5% to 6%, which is a big uptick in the back half. Can you touch on where you're putting that development? A: Keith File, President and CEO: We are investing in our team and more headcount across our business in core areas like spine, trauma, joints, and some in neuro and pain, as well as software. The broadness of the 5% to 6% gets back to the timing of when those heads come on board in the back half of the year. Kyle Klein added that there was some delay in investment, but there will be a significant ramp in spend in the back half. Q: Why the decision not to bump up the revenue guide given the performance this quarter? A: Kyle Klein, CFO: We had a beat by a little under $7 million, so a beat but not a significant one. The change in enabling tech strategy and Nevro finding the bottom have us cautious in terms of the second half. We had a strong first half, but we want to remain cautious and appropriate with our guidance range. Q: Can you talk about the momentum in underlying placements with the flexible leasing model and the pull-through of the spine business through the robots? A: Keith File, President and CEO: This year is a transition year for the more flexible options. The majority of our units moved were still outright purchases, but the mix is starting to shift. The goal is to drive incremental implant pull-through, service revenue, and disposables. There will be a lag until those sales kick in, but the goal is to drive enduring musculoskeletal growth in U.S. and international spine. Q: Can you discuss the momentum in the Nevro sales force expansion and the confidence in that business growing next year, as well as the margin improvement? A: Keith File, President and CEO: We rehired about 75% of the open positions in Q2 and are still hiring. With that comes training. We want them to be aggressive in the field to drive trial volumes, which are an early indicator of future sales. We expect to see improvement translate into sales in Q4. Kyle Klein added that the margin improvement is due to synergy actions taken in the back half of 2025, which are now showing up in the P&L with over 20% EBITDA margin. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Globus Medical, Inc. GMED used its second-quarter 2026 call to emphasize margin execution and continued spine share gains, while management flagged Nevro and Enabling Technologies as risks within the second-half outlook. GMED’s second-quarter Non-GAAP EPS of $1.34 beat the $1.12 Zacks Consensus Estimate. Revenues of $789.61 million also topped the $786.86 million estimate. Globus Medical, Inc. price-consensus-eps-surprise-chart | Globus Medical, Inc. Quote The company raised full-year 2026 non-GAAP EPS guidance to $4.95-$5.05 from $4.70-$4.80 but kept revenue guidance at $3.18-$3.22 billion. Keith Pfeil, president and CEO, said second-quarter revenues grew 6% as reported and 9% excluding Nevro, led by 7% U.S. Spine growth and 14% International Spine growth. Pfeil said competitive recruiting, robotics pull-through and product launches continued supporting U.S. Spine. Competitive hires doubled from the first quarter. Kyle Kline, CFO, called U.S. Spine's result its fifth consecutive quarter of above-market growth and said management is targeting sustained double-digit International Spine growth in the second half. Adjusted gross margin reached 69.4%, up 200 basis points year over year, supported by fixed-cost leverage, favorable mix and manufacturing and supply-chain initiatives. Adjusted EBITDA margin rose to 35.4% from 28.0%. Kline linked the higher earnings outlook to first-half margin expansion and operating leverage. Kline reiterated a 69%-70% adjusted gross margin range for 2026 and said the company expects to reach the low 70s by year-end. Pfeil said management remains confident in returning to the mid-70s in 2027. A Jefferies analyst asked whether management favored any point inside the full-year revenue range. Kline declined to narrow it and identified Enabling Technologies and Nevro as downside risks. A Piper Sandler analyst asked why Globus Medical did not raise revenue guidance. Kline said management preferred to remain cautious because of the Enabling Technologies strategy shift and the work still required to stabilize Nevro. A BMO analyst pressed on U.S. Spine growth. Pfeil said second-half comparisons become more difficult, but management remained confident in the business. Enabling Technologies revenues fell 25.8% to $26.1 million as Globus Medical continued shifting toward flexible capital-acquisition options beyond outright purchases. Pfeil said deployed ExcelsiusGPS and ExcelsiusHub units, whether sold, leased or rented, increased 11% sequentially and 25% year over year. He characterized 2026 as a transition year. In Q&A, Pfeil also said the objective is to place capital systems and then generate implant, disposable and service revenues after customers are trained and utilization builds. Nevro revenues declined 14.3% year over year in the second quarter and slipped $1.7 million sequentially, while stand-alone adjusted EBITDA margin improved to 22.4% from negative 1.4%. Roughly 75% of open sales roles were filled during the quarter. Management expects trial volumes to improve through the second half and return to historical levels late in the fourth quarter. Asked by a Truist analyst about Nevro's cadence and M&A, the CEO said the immediate focus is stabilization and a return to growth, with no specific Nevro M&A commentary. Pfeil said Globus Medical has more than 60 product-development projects underway and plans to launch its patient-specific SCRIPT lumbar spacer and rod systems later in the third quarter. Kline said R&D spending should rise in the second half as the company adds development resources, while full-year R&D remains targeted at 5%-6% of net sales. He said capital allocation continues to prioritize internal product investment, share repurchases and complementary M&A. Globus Medical repurchased $136.1 million of stock in the quarter. Management's tone combined confidence in spine growth and margin execution with caution around businesses still being reset. The unchanged revenue range reflects that balance. Pfeil and Kline kept the longer-term focus on product development, sales-force expansion and disciplined capital use, while Nevro and Enabling Technologies remain execution priorities. GMED currently carries a Zacks Rank #3 (Hold), with a Growth Score of A, Value Score of B, Momentum Score of D and VGM Score of B. The A and B grades are favorable style readings, while the D Momentum Score is weaker. Zacks Style Scores complement the Rank, with the strongest combinations pairing a Zacks Rank #1 (Strong Buy) or 2 (Buy) with A or B Style Scores. GMED currently has a #3 rank, which can change as earnings estimates are revised after the just-reported results. You can see the complete list of today’s Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Globus Medical, Inc. (GMED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

AUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026. Second Quarter 2026: Worldwide net sales were $789.6 million, an increase of 5.9%, or an increase of 5.6% on a constant currency basis. GAAP net income for the quarter was $151.6 million. GAAP diluted earnings per share (“EPS”) was $1.10, a decrease of 26.2%, primarily driven by the bargain purchase gain of $110.5 million recognized in the prior year quarter related to the Nevro acquisition. Non-GAAP diluted EPS was $1.34, an increase of 55.8%. “Momentum continued into the second quarter with 6% overall revenue growth, or 9% growth excluding Nevro, driven by share gains across a majority of our underlying businesses, most notably US Spine, growing 7% and International Spine, growing 14% as-reported and 12% on a constant currency basis,” commented Keith Pfeil, President and Chief Executive Officer. “The depth of our product portfolio and exclusive selling model positions us to lead with innovation and commercial outreach, driving our ability to grow share over the long-term. Our priority remains centered on achieving improved surgical outcomes through the Globus ecosystem, bringing together patient selection, surgical techniques with complementary implants and technology to drive the surgical procedure, through a closed-loop surgical intelligence ecosystem.” “US Spine, again, led the way in growth for the organization, marking our fifth straight quarter of above-market revenue growth, with continued strength across our entire product portfolio. This broad-based growth, paired with adjusted gross margin expansion of 200 basis points compared to the second quarter of the prior year, drove record second quarter non-GAAP net income and diluted earnings per share,” said Kyle Kline, Chief Financial Officer. “The strength of our second-quarter performance reflects disciplined execution across the business, including margin expansion, operating leverage, and synergy realization, which position us to deliver sustained earnings growth, and enhanced shareholder returns throughout the year.” Worldwide net sales for the second quarter of 2026 were $789.6 million, an as-reported increase of 5.9% over the second quarter of 2025. U.S. net sales for the second quarter of 2026 increased by 3.0% compared to the second quarter of 2025. International net sales increased by 18.0% over the second quarter of 2025 on an as-reported basis and increased by 16.2% on a constant currency basis. GAAP net income for the second quarter of 2026 was $151.6 million, a decrease of 25.3% over the same period in the prior year. The decrease in GAAP net income was primarily driven by the bargain purchase gain of $110.5 million recognized in the prior year quarter related to the Nevro acquisition. GAAP diluted EPS for the second quarter was $1.10, compared to $1.49 for the second quarter of 2025, a decrease of 26.2%. Non-GAAP diluted EPS for the second quarter of 2026, which excludes, among other costs, amortization of intangibles, merger and acquisition-related costs, and restructuring-related costs, was $1.34, compared to $0.86 in the second quarter of 2025, an increase of 55.8%. 2026 Annual Guidance The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.95 to $5.05 from the previous range of $4.70 to $4.80. Conference Call Information Globus Medical will hold a teleconference to discuss its 2026 second quarter results with the investment community at 4:30 p.m. Eastern Time today. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at http://www.investors.globusmedical.com/news-events/events-webcasts. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The audio archive will be available after the call on the Investor page of the Globus Medical website. About Globus Medical, Inc. Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com. Non-GAAP Financial Measures To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), management uses certain non-GAAP financial measures. For example, non-GAAP Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation expense, provision for litigation, merger and acquisition related costs, restructuring related costs, certain foreign currency acquisition-related impacts, bargain purchase gains, and gains and losses from strategic investments, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. We no longer include acquisition of in-process research and development as an adjustment to non-GAAP Adjusted EBITDA. Our management also uses non-GAAP Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Merger and acquisition related costs represents the change in fair value of business-acquisition-related contingent consideration; costs related to integrating recently acquired businesses, including but not limited to costs to exit or convert contractual obligations, severance, retention bonus, duplicative costs and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees. Restructuring related costs include severance, retention bonus, accelerated stock-based compensation expense, legal and tax fees for legal entity reorganization and costs associated with consolidating facilities. We also adjusted for certain foreign currency impacts related to the acquisition costs and gains/losses on strategic investments within other assets as we believe these impacts are not a measure of our operating performance. In addition, for the period ended June 30, 2026 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted EPS, which represent net income and diluted EPS excluding the provision for litigation, amortization of intangibles, merger and acquisition related costs, restructuring related costs, certain foreign currency impacts, gains and losses from strategic investments, bargain purchase gains, certain income tax net benefits and non-recurring tax adjustments, and the tax effects of all of the foregoing adjustments. We no longer include acquisition of in-process research and development as an adjustment to non-GAAP net income. We also present non-GAAP gross profit, which excludes the impacts of any inventory acquisition-related costs within cost of goods sold. The tax effect adjustment represents the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income. The tax impact of the non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments, unless the underlying item has a materially different tax treatment, in which case the estimated tax rate applicable to the adjustment is used. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of the foregoing items, which we believe are not reflective of underlying business trends. Additionally, for the period ended June 30, 2026 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, the non-GAAP measure of constant currency net sales growth is calculated by translating current year net sales at the same average exchange rates in effect during the applicable prior year period. We believe constant currency net sales growth provides insight to the comparative increase or decrease in period net sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates. We are also presenting base business revenue growth, excluding the contribution from Nevro Corp. (“Nevro”), which we acquired in 2025. We believe these provide insight to how the Company is performing without the impact of our most recent acquisition. Non-GAAP Adjusted EBITDA, non-GAAP net income, non-GAAP diluted EPS, non-GAAP gross profit, free cash flow, constant currency net sales growth, base business revenue growth, and day-adjusted basis sales are not calculated in conformity with GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of these non-GAAP measures may differ from that of other companies and therefore may not be comparable. The tables included in this release reconcile the GAAP financial measures to the non-GAAP financial measures discussed above for the three months ended June 30, 2026. We are unable to present a quantitative reconciliation of our expected fully diluted GAAP EPS to non-GAAP diluted EPS as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of provision for litigation, amortization of intangibles, merger and acquisition-related costs, restructuring related costs, certain foreign currency acquisition-related impacts, bargain purchase gains, certain income tax net benefits from non-recurring tax adjustments, gains and losses from strategic investments, and the tax effects of all of the foregoing adjustments. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Income. Safe Harbor Statements All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties, and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company”, “Globus”, “Globus Medical”, “we”, “us”, and “our” refers to Globus Medical, Inc. The following tables reconcile GAAP to non-GAAP financial measures. (1)  Merger and acquisition-related costs represent certain costs associated with acquisitions. These costs, presented on a before-tax effect basis, are included in Non-GAAP Merger and Acquisition-related Costs Table. (a)  Primarily comprised of legal fees, advisory and consulting fees.(b)  Primarily comprised of severance, share based compensation and termination fees. (1)  See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table for the detail for these costs. (1) See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table above for the detail of these costs. *Amounts may not add due to rounding. Investor Contact: Brian KearnsSenior Vice President, Corporate Development and Investor RelationsPhone: (610) 930-1800Email: [email protected]

Globus Medical (GMED) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $0.86 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +19.64%. A quarter ago, it was expected that this medical device company would post earnings of $0.92 per share when it actually produced earnings of $1.12, delivering a surprise of +21.74%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Globus Medical, which belongs to the Zacks Medical - Instruments industry, posted revenues of $789.61 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.35%. This compares to year-ago revenues of $745.34 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Globus Medical shares have lost about 7.8% since the beginning of the year versus the S&P 500's gain of 12.8%. While Globus Medical has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Globus Medical was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.16 on $795.09 million in revenues for the coming quarter and $4.74 on $3.2 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, SINTX TECHNOLOGIES, INC. (SINT), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 11. This company is expected to post quarterly loss of $0.69 per share in its upcoming report, which represents a year-over-year change of +24.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. SINTX TECHNOLOGIES, INC.'s revenues are expected to be $0.4 million, up 166.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Globus Medical, Inc. (GMED) : Free Stock Analysis Report SINTX TECHNOLOGIES, INC. (SINT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research